Rheumatologic Manifestations of Sarcoidosis

Sweiss, Nadera J.; Patterson, Karen; Sawaqed, Ray; Jabbar, Umair; Korsten, Peter; Hogarth, Kyle; Wollman, Roy; Garcia, Joe G.N.; Niewold, Timothy B.; Baughman, Robert P.

doi:10.1055/s-0030-1262214

Cited by 84 publications

(73 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acute myositis is characterized by non-specific symptoms such as fever and fatigue associated with muscle swelling, disabling pain, and sometimes contractures. The chronic form affects most often multiple groups of muscles, while the nodular involvement presents as multiple tumor-like masses found on muscle palpation (64).…”

Section: Sarcoidosis-related Myopathymentioning

confidence: 99%

Challenges in the diagnosis and treatment of neurosarcoidosis

et al. 2015

View full text Add to dashboard Cite

The diagnosis and treatment of neurosarcoidosis can be very challenging for several reasons. It affects clinically 5%-10% of sarcoidosis patients, but can be found in up to 25% of autopsies. These data reveal that a high percentage of asymptomatic or misdiagnosed cases can be missed at an initial diagnostic approach. Clinical and imaging findings are often non-specific since they can be found in a large number of neurological disorders. Histopathology can also be confounding if not performed by an expert pathologist and not placed in an appropriate clinical context. In this review, we discuss clinical features, laboratory findings, imaging, and histology of neurosarcoidosis, and we report current evidence regarding drug therapy. We conclude that a correct diagnostic approach should include a multidisciplinary evaluation involving clinicians, radiologists, and pathologists and that future studies should evaluate the genetic signature of neurosarcoidosis as they could be helpful in the assessment of this uncommon disease. With head-to-head comparisons of medical treatment for neurosarcoidosis still lacking due to the rarity of the disease and an increasing number of immunomodulating therapies at hand, novel therapeutic approaches are to be expected within the next few years. Key messages Neurosarcoidosis is a rare disorder that affects clinically 5%-10% of sarcoidosis patients, but can be found in up to 25% of autopsies, revealing that a high percentage of asymptomatic or misdiagnosed cases can be missed at an initial diagnostic approach. A multidisciplinary evaluation is useful to achieve a correct diagnosis because clinical and imaging findings are often non-specific. Corticosteroids are the first-line treatment for neurosarcoidosis, followed by steroid-sparing immune-modulating agents if prednisone therapy is insufficient. Dear Author, Please check these proofs carefully. It is the responsibility of the corresponding author to check against the original manuscript and approve or amend these proofs. A second proof is not normally provided. Informa Healthcare cannot be held responsible for uncorrected errors, even if introduced during the composition process. The journal reserves the right to charge for excessive author alterations, or for changes requested after the proofing stage has concluded.The following queries have arisen during the editing of your manuscript and are marked in the margins of the proofs. Unless advised otherwise, submit all corrections using the CATS online correction form. Once you have added all your corrections, please ensure you press the ''Submit All Corrections'' button.Please review the table of contributors below and confirm that the first and last names are structured correctly and that the authors are listed in the correct order of contribution. The diagnosis and treatment of neurosarcoidosis can be very challenging for several reasons. It affects clinically 5%-10% of sarcoidosis patients, but can be found in up to 25% of autopsies. These data reveal that a high percenta...

show abstract

Section: Sarcoidosis-related Myopathymentioning

confidence: 99%

Challenges in the diagnosis and treatment of neurosarcoidosis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Eklemde efüzyon, sinovit ve sinovyumda nodüler proliferasyon geliflebilir. [2] Kronik sarkoid artriti, tipik olarak sistemik tutulumla seyreden sarkoidoz olgular›nda görülür. Genellikle parankimal akci¤er hastal›¤› ve ACE yüksekli¤i ile birliktelik gösterir.…”

Section: Kas ‹Skelet Sistemi Bulgular› Eklem Tutulumuunclassified

“…Göreceli olarak s›k görülen bir hastal›k olmas›na ve tedavisinde baflta kortikosteroidler (KS) olmak üzere çok de¤iflik ajanlar kullan›lmas›na ra¤men, sarkoidoz tedavisinde Food and Drug Administration (FDA) taraf›ndan onaylanm›fl hiçbir ilaç olmamas› ilginçtir. [1,2] Pratik olarak sarkoidoz denildi¤inde, romatoloji hekiminin akl›na, öncelikle ayak bileklerini tutan renkli artrit, bacaklarda eritema nodozum lezyonlar›, sistemik inflamasyon bulgular›, hiperkalsemi, akci¤er grafisinde bilateral hiler dolgunluk ve serum anjiyotensin konverting enzim (ACE) düzeyinde yükseklik gelir. Ancak, eklem bulgular› d›fl›nda, sarkoidoz romatoloji hekiminin karfl›s›na kas, kemik, damar ve tükürük bezi tutulufluyla da gelebilir.…”

unclassified

“…Hiperürisemiye neden olabildi¤i için, gut hastal›¤› ile kar›flabilir. [2] Bu derlemenin amac› baflta gö¤üs hastal›klar› olmak üzere, t›bb›n birçok uzmanl›k alan›n› ilgilendiren ve çok farkl› klinik tablolarla neden olabilen sarkoidozun tüm yönleriyle tart›fl›lmas› de¤ildir. Bu derlemede özellikle sarkoidozun romatoloji uzman›n› ilgilendiren yönlerinin üze-rinde durulmas› hedeflenmifltir.…”

unclassified

See 1 more Smart Citation

Romatolog gözüyle sarkoidoz

Tarhan¹

2013

RAED Derg

View full text Add to dashboard Cite

“…Sarcoidosis is a systemic disorder characterized by a non-caseating granulomatous inflammation which can affect virtually any organ, including lung, joints and skin [85]. In broncheoalveolar lavage fluid of sarcoidosis patients, HNP-levels were increased approximately 10-fold.…”

Section: Sarcoidosismentioning

confidence: 99%

Defensins: Potential Effectors in Autoimmune Rheumatic Disorders

Vordenbäumen

Schneider

2011

Polymers

View full text Add to dashboard Cite

Abstract:Defensins are small cationic peptides with antimicrobial properties. They constitute a highly conserved innate immune defense mechanism across species. Based on the arrangement of disulfide-bonds, α-and β-defensins are distinguished in humans. Both types of defensin comprise several distinct molecules that are preferentially expressed at epithelial surfaces and in blood cells. In the last decade, multiple immunomodulatory functions of defensins have been recognized, including chemotactic activity, the promotion of antigen presentation, and modulations of proinflammatory cytokine secretion. These findings suggested a role for defensins not only as a first line of defense, but also as connectors of innate and adaptive immune responses. Recently, increasingly accumulating evidence has indicated that defensins may also be involved in the pathogenesis of autoimmune rheumatic disorders such as systemic lupus erythematosus and rheumatoid arthritis. The current review summarizes the data connecting defensins to autoimmunity.

show abstract

Rheumatologic Manifestations of Sarcoidosis

Cited by 84 publications

References 71 publications

Challenges in the diagnosis and treatment of neurosarcoidosis

Challenges in the diagnosis and treatment of neurosarcoidosis

Romatolog gözüyle sarkoidoz

Defensins: Potential Effectors in Autoimmune Rheumatic Disorders

Contact Info

Product

Resources

About